Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of capivasertib plus fulvestrant in patients with advanced estrogen receptor-positive breast cancer.